ES-2

ES-2/ES-2细胞系/ES-2细胞株/ES-2人卵巢癌细胞

Cell line name ES-2

Synonyms ES2

Accession CVCL_3509

Resource Identification Initiative To cite this cell line use: ES-2 (RRID:CVCL_3509)

Comments Problematic cell line: Probably misclassified. It is dubious that this cell line originates from an African American 47 year old patient diagnosed with an ovarian clear cell adenocarcinoma. Immunohistochemical and qPCR analysis as well as its mutational profile support an ovarian serous adenocarcinoma origin (PubMed=25049276; DOI=10.26502/ogr072). Furthermore its genome ancestry clearly shows a Caucasian/European decent (PubMed=30894373) which is confirmed by mtDNA haplotyping (DOI=10.26502/ogr072).

Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: MD Anderson Cell Lines Project.

Part of: OCCP ovarian cancer cell line panel.

Population: Caucasian.

Doubling time: 31.11 hours (JWGray panel); ~24 hours (ATCC=CRL-1978).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: CRISPR phenotypic screen.

Omics: Deep exome analysis.

Omics: Deep quantitative phosphoproteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Genome sequenced.

Omics: Protein expression by reverse-phase protein arrays.

Omics: Secretome proteome analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Omics: Transcriptome analysis by serial analysis of gene expression (SAGE).

Derived from site: In situ; Ovary; UBERON=UBERON_0000992.

PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567

Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K., Hirohashi S., Inazawa J., Imoto I.

Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.

Cancer Res. 67:7095-7105(2007)

 

PubMed=18560578; DOI=10.1371/journal.pone.0002425; PMCID=PMC2409963

Faca V.M., Ventura A.P., Fitzgibbon M.P., Pereira-Faca S.R., Pitteri S.J., Green A.E., Ireton R.C., Zhang Q., Wang H., O'Briant K.C., Drescher C.W., Schummer M., McIntosh M.W., Knudsen B.S., Hanash S.M.

Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains.

PLoS ONE 3:E2425-E2425(2008)

 

PubMed=18720132; DOI=10.1080/10717540802329183

Serikawa T., Kikuchi H., Oite T., Tanaka K.

Enhancement of gene expression efficiency using cationic liposomes on ovarian cancer cells.

Drug Deliv. 15:523-529(2008)

 

PubMed=20081105; DOI=10.1210/me.2009-0295; PMCID=PMC2817607

Nagaraja A.K., Creighton C.J., Yu Z.-F., Zhu H.-F., Gunaratne P.H., Reid J.G., Olokpa E., Itamochi H., Ueno N.T., Hawkins S.M., Anderson M.L., Matzuk M.M.

A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.

Mol. Endocrinol. 24:447-463(2010)

 

PubMed=20204287; DOI=10.3892/or_00000728; PMCID=PMC2909445

Langland G.T., Yannone S.M., Langland R.A., Nakao A., Guan Y.-H., Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.

Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.

Oncol. Rep. 23:1021-1026(2010)